AnnuAl report - Génome Québec

Annual report
2011/2012
Nature
helping
nature
A single test
to identify
5 hereditary
diseases
A diagnostic
microlab
on a CD
Genomics
supporting
forestry
Demystifying
childhood
brain cancer
Table of Contents
VISION
Génome Québec
Genomics is a
driving force critical
to Québec’s future.
CORPORATE INFORMATION
For more information, please contact the Public Affairs and
Communications Department at 514 398-0668 or Louise Thibault
by e-mail at [email protected]
Head office Génome Québec • 630 René-Lévesque Blvd. West,
Suite 2660, Montréal, Québec H3B 1S6 • 514 398-0668 •
Fax 514 398-0883 • [email protected] •
www.genomequebec.com
Auditors KPMG LLP • 600 de Maisonneuve Blvd. West, Suite 1500,
Montréal, Québec H3A 0A3 • www.kpmg.ca
Legal adviser M Jean Brunet • Stein Monast, S.E.N.C.R.L •
70 Dalhousie Street, Suite 300, Québec, Québec G1K 4B2
e
Genome Canada • 150 Metcalfe Street, Suite 2100, Ottawa, Ontario
K2P 1P1 • www.genomecanada.ca
Ministère du Développement économique, de l’Innovation et
de l’Exportation du Québec • 710 Place D’Youville, 3rd floor,
Québec (Québec) G1R 4Y4 • www.mdeie.gouv.qc.ca
McGill University and Génome Québec Innovation Centre •
740 Docteur-Penfield Ave., Montréal, Québec H3A 1A4 •
514 398-7211 • Fax 514 398-1790 •
[email protected]
Génome Québec and Centre hospitalier affilié universitaire régional
de Chicoutimi Biobank • 305 St-Vallier Street, Chicoutimi, Québec
G7H 5H6 • 514 398-7211 • [email protected]
ISBN 978-2-9811988-2-2
Legal deposit - Bibliothèque et Archives nationales du Québec
Legal deposit - Library and Archives Canada, 2012
Cover page:
Representation of 3D map of the human genome
Image: Leonid A. Mirny and Erez Lieberman-Aiden
Science - 9 October 2009: 289-293
(Lieberman, van Berkum, et al. Science 2009)
02
MESSAGE FROM THE CHAIRMAN
OF THE BOARD
03
MESSAGE FROM THE PRESIDENT AND CEO
SCIENTIFIC affairs ACTIVITY REPORT
04
2012 Large-Scale Applied Research
Project Competition
05
CEEHRC Competitions
05
Génome Québec Initiatives
TECHNOLOGICAL CENTRES
ACTIVITY REPORT
06The McGill University and Génome Québec
Innovation Centre
07
Génome Québec and Centre hospitalier affilié
universitaire régional de Chicoutimi Biobank
PUBLIC AFFAIRS AND
COMMUNICATIONS ACTIVITy REPORT
08Public Affairs
09-10Communications
11
FINANCIAL ACTIVITY REPORT
12
13
FINANCIAL STATEMENTS
Statement of Financial Position
Statement of Operations
14
LISTS OF MEMBERS OF THE BOARD OF
DIRECTORS AND COMMITTEES
15
LIST OF EMPLOYEES
16
LARGE-SCALE PROJECTS OUTCOMES
17
ASSESSMENT OF COMPLETED PROJECTS
Génome Québec
Message from the
CHAIRMAN OF THE BOARD
For over ten years now, Génome Québec has played a strategic role as an intermediary between
funding agencies and the genomics scientific community in Québec. Since its founding in 2000, our
organization has invested more than $500 million to finance over 60 top-notch research projects and
establish cutting-edge technological centres. Today, we can say with confidence that our approach
has borne fruit, which is why we plan on continuing down the same path.
With a solid foundation now in place, it is only fitting that our second decade be marked by resultsoriented initiatives that promise to bring even more of the benefits of genomics to society. In this regard,
this year we will be adding a new dimension to our activities: a philanthropic program to support
foundation-backed projects. Through this initiative, stakeholders with a vested interest in genomics
will have the opportunity to speak to our leadership status and promote a broader understanding of the
advantages of genomics.
The new program will help better align our organization with the needs of patients,
government departments and other potential genomics end users. The nature of the
partnerships will vary depending on the context. It could involve, for instance, helping
an organization draft a scientific development plan or a research support program
linked to their objectives. We have already taken concrete action in this respect by
launching partnerships with the Leukodystrophies Foundation, the Foundation of
Ataxia Charlevoix-Saguenay and the Association de l’acidose lactique.
Through these activities, which will span three to five years, Génome Québec
hopes not only to serve as a strategic intermediary between funding bodies and
researchers but also to act as an interface between these two groups and the various
public interest organizations. I am convinced that the coming together of all these
parties will accelerate the discovery and innovation processes and allow genomics
to achieve its full potential.
I also wish to reiterate the importance of banding together to highlight the key economic role played
by genomics. Genomics technology has the potential to transform our world by solving some of the
most pressing issues in human health, forestry and the environment. This is why our goal is to find ways to
facilitate the transfer of discoveries into new applications.
In closing, I would like to thank our board members for graciously putting their expertise to work for our
organization. Their contribution is such a valuable asset. I also extend my sincere thanks to Marc LePage
and his entire team for their excellent work.
Martin Godbout
Chairman of the board
02
Génome Québec
MESSAGE FROM THE
President and CEO
Just over ten years ago, during the booming 2000s, a group of pioneering
scientists embarked on a major project that would lead to the creation of
Genome Canada. The human genome had just been sequenced and the
United States was announcing huge investments in genomics. I was among those convinced that the
Canadian government needed to expend the necessary efforts to put Canada on the map as a leader
in genomics.
Since then, through a well-established critical mass and cutting-edge infrastructures, we are pleased
to see that Canada is now competitive and recognized internationally. But the rules of the game have
since changed.
After seven years abroad, I have returned to a very different landscape here in Canada. The world of
research has evolved considerably. What seemed impossible before is now par for the course.
Highlighting the results of basic research has become one of the ways to attract funding. What is more,
the current trend in funding now increasingly favours applied research.
My arrival at the helm of Génome Québec coincides with the launch of Genome Canada’s competition
in personalized medicine. As I perused the evaluation criteria, I was pleasantly surprised to note the
prominence given to socioeconomic benefits and potential short-term applications. Ten years ago, such
standards never would have been accepted by the scientific community. While this represents a huge
paradigm shift and an equally major challenge, I sense a willingness to adapt to this change. Initially,
research teams were headed by genomics scientists, who worked on transferring science from the lab
to the clinic. Today, the opposite is true; a growing number of clinicians are leading teams, as real
needs form the basis of their scientific inquiry. To be sure, this is a major shift, indicative of the road
travelled thus far. It is now up to us to capitalize on this change in dynamic in order to rebuild the
Québec advantage and make Québec a leader in personalized medicine.
The year 2012-2013 will be critical from a strategic perspective. The 2013-2016 Québec Research and
Innovation Strategy (QRIS-III) is already being drafted. At Génome Québec, we take this exercise
seriously, since the strategy constitutes one of our main funding vehicles. Making genomics one of
the economic pillars of Québec remains a key priority and doing so requires creativity on several fronts:
accelerating social and economic returns, publicizing research results, diversifying funding sources and
expanding our international influence, to name a few. We will develop results-oriented concepts and
capitalize on our assets and strategic sectors: health, forestry, the environment and mining. With a bold
yet realistic vision, we will build on the new life sciences business model that is currently emerging here
in Québec.
Genomics is entering a new era, and together with our institutional, industrial and social partners, we will
launch into this transition with success. I wish to thank the management team and all staff for embarking
on this great journey with me!
Marc LePage
President and CEO
03
Génome Québec
SCIENTIFIC
ACTIVITY REPORT
Demystifying
Pediatric
Brain Cancer:
Scientific Breakthrough
in our Understanding
of Glioblastomas
Brain tumours are the deadliest of all and the
second most common type of childhood cancer.
Sadly, brain tumours,
including lethal glio­
blastomas, are a death
sentence for 200
Canadian children
every year. After two
years of research,
Dr. Nada Jabado and
her team at McGill
University Health
Centre (MUHC) in
Montréal have discovered why glioblastomas
are unresponsive to
standard chemotherapy
and radiation. The answer
was in our genes!
This discovery paves
the way for additional
research into more
effective and productive
ways of treating children
with glioblastomas.
To learn more, click here.
Dr. Nada Jabado
GENOME CANADA
COMPETITIONS
2012 Large-Scale Applied
Research Project Competition
Launched in January 2012, Genome Canada’s 2012 Large-Scale Applied
Research Project Competition focuses on the application of genomics to
personalized health. The competition will support projects that lead to
the development of tools and solutions for short-term use in personalized
medicine. The research is also expected to contribute tangible
socioeconomic benefits to improve the quality of care in Canada and
the cost-effectiveness of its health care systems.
To help researchers succeed in the nation-wide competition, Génome Québec
gave them substantial support in preparing their requests. Researchers were
able to participate in a forum organized by Génome Québec on how to best
present the expected socioeconomic outcomes of their projects. They also
had the chance to consult health economics experts. In addition, Génome
Québec facilitated the pairing of research teams with end users – as required
by the competition – and with GE3LS* researchers to address this aspect of
their requests.
Our organization further helped to expand co-funding opportunities on
two fronts. First, we committed to co-funding Québec researchers who
use CARTaGENE biobank data and samples as part of their research.
Then, through Génome Québec’s involvement, the Foundation of AtaxiaCharlevoix-Saguenay and the Leukodystrophies Foundation agreed to
serve as co-funding partners for Canadian projects.
The deadline for pre-applications was May 10, 2012. Researchers whose
projects were selected at this stage have until August to submit their full
application. The results of the competition will likely be announced in
December 2012.
* Study of the ethical, environmental, economic, legal and social aspects
of genomics
Entrepreneurship Education in Genomics (EEG)
A Québec project won the Genome Canada Entrepreneurship Education in Genomics (EEG) competition, as announced
in September 2011. Led by Denis J. Garand of the Department of Management at Université Laval, the initiative Boosting
Entrepreneurial Skills & Training in Genomics: BEST in Genomics! was awarded $1.2 million over three years to help
genomics researchers from Québec and the Maritimes develop their entrepreneurial skills and translate their
discoveries into marketable applications. The funds were provided by Genome Canada (50%), Génome Québec (25%)
and other partners (25%).
04
CEEHRC
Competitions
The Canadian Epigenetics*, Environment and Health Research
Consortium, (CEEHRC), an initiative of the Canadian Institutes
of Health Research, launched two new funding opportunities in
summer 2011. The Catalyst Grant will support small-scale projects
aiming to develop new technologies and innovative approaches
with the potential to transform epigenetic research. As for the
Epigenomics Platform competition, it will serve to implement a
Canadian epigenetic platform to be used as a reference point
for epigenomics researchers and coordinate research efforts in
the field. Génome Québec has been a CEEHRC partner since the
inception of the initiative.
* Epigenetics is the study of how the environment and an individual’s
history affect genes expression.
Genomics could have
answers to Forest
Industry renewal!
The forest industry is undergoing massive transforma­
tion. Timber resources – the raw material of forests
– are dwindling, and replenishing them requires time
and patience. In a highly competitive world market,
every minute counts. That’s why John MacKay and
Jean Bousquet, researchers at Université Laval in Québec
City, began searching for innovative ways to ensure
the sustainable development of our forests. Their
approach: genomics.
GÉNOME QUÉBEC INITIATIVES
Genomics is being used to pinpoint the strengths and
weaknesses of each species under study. This, in turn,
helps to single out the best trees for reforestation
and identify the varieties most likely to adapt to new
climatic conditions.
Québec Vert Competition
To learn more, click here.
Spring 2011 marked the launch of the Génome Québec funding
competition, Québec Vert, in support of pilot projects that
rely on genomics to solve issues related to ecosystem health.
Génome Québec is investing $300,000 in the projects of the
three researchers selected at the end of the competition in
March 2012. The researchers were François Belzile of Université
Laval, Connie Lovejoy of Université Laval and Vincent Martin of
Concordia University.
The research will shed light on areas such as fossil fuel
dependency, the Arctic environment and sustainable
development. It will also afford researchers the opportunity to
gather relevant data for the subsequent launch of large-scale
genomics environmental research in view of provincial, federal
and international competitions.
Jean Bousquet and John MacKay
The Québec-Ontario Life Sciences Corridor
The Québec-Ontario Life Sciences Corridor was established to develop opportunities for partnership and cooperation
built on the excellence in life sciences research and innovation of both provinces.
As part of this initiative, Génome Québec, the Québec Consortium for Drug Discovery and the Ontario Genomics Institute
will be hosting annual networking events to facilitate the creation of joint projects between Québec and Ontario scientists
working in personalized medicine and the launch of university-industry partnerships.
Some 35 Québec and Ontario researchers and 15 private companies, including pharmaceutical and biotech firms,
participated in the first event held in Toronto on November 1, 2011. We are pleased to announce that during the event
a Québec researcher joined forces with an Ontario-based industrial partner. The synergy shared by both teams led to
the submission of a superior quality project to Genome Canada’s personalized health competition.
05
Génome Québec
TECHNOLOGICAL CENTRES
ACTIVITY REPORT
The McGill University and Génome Québec
Innovation Centre
The Innovation Centre reported the strongest revenue in its history this year,
a total of $11.6 million or a 18% increase compared to last year. The number of
clients served also rose by 2%, reaching 797 research teams. Of that number,
an impressive 93 percent mentioned being satisfied or very satisfied with the
services they received, as reported in a survey administered annually.
This year also marked the completion of a major genotyping project
commissioned by the Collaborative Oncological Gene-environment Study
(COGS), an extensive international study based in Cambridge, UK involving
40 countries. The Innovation Centre conducted genotype testing on 105,000
of the 200,000 samples, representing more than half of the overall tests.
Five other technological centres in Europe and the United States carried out
the remainder.
The Innovation Centre also completed the upgrade of its high throughput
sequencing capacity launched in 2010. The Centre now has at its disposal
18 next generation sequencers, three times more than two years ago. Its
IT infrastructures and bioinformatics tools were also updated in order to
support the new instruments.
The Innovation Centre is extremely well positioned to continue its growth in
the future. In addition to pursuing its regular activities, in the next year it will
be developing a new field of expertise: clinical services. This new service is
designed for clinician-researchers who wish to use genomics for diagnostic
and therapeutic purposes.
Lactic Acidosis:
Better Understanding
for Better Prevention
Just over a decade ago, Pierre Lavoie was already cycling hundreds of kilometres to raise
awareness for lactic acidosis. The inherited recessive disorder, which is especially present
in the Saguenay-Lac-Saint-Jean region, robbed him of two of his children.
In this region, many children are affected by the inherited disorder. In fact, 1 in 22 people
carry the genetic mutation, a situation that is sufficiently serious to warrant making lactic
acidosis a public health issue.
Fortunately, through genomics, it is now possible, with a single test that costs only $20, to screen for five different diseases (lactic
acidosis, ataxia of Charlevoix-Saguenay, cystic fibrosis, motor and sensory neuropathy and tyrosinemia).
To learn more, click here.
06
Decontaminating
Soils with Mother
Nature’s Help
Génome Québec and Centre
hospitalier affilié universitaire
régional de Chicoutimi Biobank
From 2009 to last year, the Biobank dedicated most
of its efforts to the management of the biological
samples collected from the 20,000 or so participants
of the CARTaGENE project. With the completion
of the data collection phase for this cohort at the
end of 2010, the Biobank’s CARTaGENE activities
slowed down considerably in 2011-2012. They now
consist mostly of quality assurance operations and
the preparation of samples for research projects.
In view of this, the diversification of its client base
has become a priority for the Biobank, which is why
it has intensified its business development efforts
this year. This will involve promoting via its Website
its long-term storage services and offering its
expertise to partners looking for support in the
efficient management of their samples in the short,
medium and long term.
Researchers Mohamed Hijri, professor of Biological
Sciences at Université de Montréal, and Franz Lang,
holder of the Canada Research Chair in Comparative
and Evolutionary Genomics and professor of
Biochemistry at the same university, are thrilled
with their recent discovery. They may just
have found a way to clean up the contaminated
sites of the entire planet! How? By combining
plants, mushrooms and bacteria! It’s a new green
technology called bioremediation and its
potential has yet to be fully unlocked.
To learn more, click here.
Another noteworthy achievement by the Biobank
in 2011-2012 was the optimization of its sample
processing methods and procedures. This initiative,
which will continue next year, is helping the Biobank
improve its performance, while meeting the strictest
standards for quality, integrity and safety.
Mohammed Hijri
Franz Lang
07
Génome Québec
Public Affairs and
Communications Activity Report
Public Affairs
Genomics Summit
The first Canadian Genomics Summit, organized by
Génome Québec in partnership with Genome Canada
and the genomics centres of British Columbia, Alberta,
Ontario, the Prairies and the Maritimes, was held in
Montréal on October 11, 2011. Bringing together close
to 90 genomics experts and influential actors in the
health sector from all parts of Canada, the event focused
on how to best apply genomics research findings to the
country’s health care systems.
The meeting was an opportunity to both recognize the
benefits of genomics for health care and discuss the
challenges of transferring knowledge and genomics
tools to health care professionals, managers and
decision makers.
10th Anniversary
On May 12, 2011, Génome Québec celebrated its 10 th anniversary
during the Celebrate 10 years for life event. Held at the Montréal
Science Centre, with Minister Clément Gignac in attendance,
it showcased the many contributions and achievements of
those who have shaped the history of genomics. Minister Gignac
used the opportunity to announce the Government of Québec’s
decision to grant $26 million to Génome Québec in support
of ongoing research and development in the field. This major
investment was met with excitement by attendees. Another high
point of the gathering of key contributors to the genomics sector
was the screening of a video featuring some of Québec’s pioneers
in genomics and highlighting the milestones of the last decade.
The video can be viewed online, click here.
08
The Federal Scene
Génome Québec also took part in two activities of the Canadian Genomics Enterprise, a collaborative network of
individuals and organizations consisting of those who fund research, those who conduct it, those equipped to translate
discoveries into applications which will benefit Canadians.
Genomics on the Hill, Ottawa
Genomics on the Hill is a unique opportunity to present Canadian researchers and their work to members of
Parliament and other federal government representatives. This year, Québec was represented by Claude
Laberge from Université Laval and Philip Awadalla from Université de Montréal of CARTaGENE and Denis J. Garand
of Université Laval for his project Boosting Entrepreneurial Skills & Training in Genomics: BEST in Genomics!
BIO International Convention
BIO International Convention, the world’s largest biotechnology conference and trade show, featured a
Canadian Pavilion presenting Canadian genomics researchers and their breakthroughs. This year’s event was
held in Washington.
Communications
Eureka! Festival
As part of its efforts to fuel the interest of youth in
science careers, Génome Québec launched the last
quest of phase 2 of Genomia at the Eureka! Festival,
held from June 17 to June 19 on the Quays of the
Old Port of Montréal. This final phase of the project
presented various careers in genomics through
fun-filled quests for players. Young people had the
chance to learn about the jobs of lab technician,
geneticist and bioinformatics specialist. This year,
some 500 people learned a bit more about the role
of a bioinformatics specialist. Since the launch of
the game in June 2009, some 212,584 visitors have
trodden upon the soil of Genomia. Developed
with financial support from the MDEIE, Genomia is
available online free of charge.
Compact Disk Has a
Promising Future in Medicine!
To treat their patients efficiently, doctors need
diagnostic tests that deliver rapid results.
Yet today’s clinical microbiology testing is
slow. This means that doctors generally have
to wait 36 to 48 hours before getting the
results that tell them exactly which microbe is
responsible for their patient’s health problem.
Dr. Michel G. Bergeron, an eminent
researcher from Université Laval, and
his team have developed a diagnostic
compact disk – a kind of miniature lab capable
of performing DNA testing to help identify
and fight viral and bacterial infections.
The diagnostic tools developed by Dr. Bergeron
led to an international partnership, which
resulted in the construction of a new BD
Diagnostics plant in Québec City. Now the
plant manufactures the tests and ships them
all over the world, employing 350 highly
skilled workers.
To learn more, click here.
Dr. Michel G. Bergeron
09
Communications
Défi Tweete tes Neurones !
On November 28, 2011, Génome Québec and
the Québec Consortium for Drug Discovery
announced the winners of Défi Tweete tes
neurones !, a competition promoting the life
sciences sector, with a special focus on medical
and biopharmaceutical research. Members of the
winning team were Cyril Bernier, Anthony Jacques
Hachez and David Pontbriand of HEC Montréal.
They earned themselves a $10,000 cheque for
their excellent campaign entitled, “Parlons-en de
vive voix.” The goal of the initiative was to raise
awareness among 18-34-year olds on the importance
of the technological advances made in life sciences
in Québec.
Other Initiatives
Génome Québec is also a member of an informal network of Québec medical and
biopharmaceutical research organizations. Working together under a banner called
Forces Vives, the group develops concerted communication initiatives to strengthen the
visibility of the Québec life sciences sector and broaden its influence among Quebecers.
Other members include the Québec Consortium for Drug Discovery, the Fonds de recherche du Québec – Santé,
Montréal InVivo, Pharmabio développement, Québec International, Canada’s Research-Based Pharmaceutical
Companies and Canada’s Medical Technology Companies.
A research Project from Université Laval wins
Genome Canada’s Entrepreneurship Education
in Genomics (EEG) Competition
Two researchers on the Québec
Science magazine top 10 discoveries
of the year list
Denis J. Garand
(La Presse, September 2011)
10
Philip Awadalla
(Québec Science, February 2012)
Vassilios Papadopoulos
(Québec Science, February 2012)
Financial Activity Report
Génome Québec
Génome Québec manages research projects funded primarily by Genome Canada and the
Ministère du Développement économique, de l’Innovation et de l’Exportation du Québec.
As at March 31, 2012, our portfolio included 39 genomics and proteomics projects. The total
budget for projects currently underway is $160 million. Génome Québec invested $33.8 million
during the 2011-2012 fiscal year. This amount, combined with the $16.3 million invested by other
partners, brings our overall injection of funds to $50.1 million.
Business volume generated by the large-scale projects during the fiscal year amounts to
$30.6 million. This year, Génome Québec launched the LSARP Competition projects (large-scale
applied research project competition), Québec Vert and recruitment programs. The ABC
Competition projects (applied genomics research in bioproducts or crops) and Génome Québec
Human Health Competition accounted for the bulk of business volume during this same period.
For the year ended on March 31, 2012, sales from our Technological Centres totalled $12.8 million,
a 5% increase from the previous year. The growth was achieved despite the transfer of the NIML
Centre during the year. Sales for the McGill University and Génome Québec Innovation Centre
rose by 18% over last year. The Technological Centres posted an excess of revenue over
expenses of $1.7 million. Of this total, $1.6 million is earmarked for the development of the
Innovation Centre’s scientific strategic plan.
General and administrative expenses* (adjusted for non-recurring expenditures) totalled
$3 million during the fiscal year, or 5.9% of total investments, compared to $3.5 million – or 7.3% –
last year. The decrease reflects the implementation of a cost-cutting plan for general and
administrative expenses. Investment revenue reached $914,255, for a return of 2.4%.
During the fiscal year, the excess of revenue over expenses totalled $1.1 million. The unrestricted
net assets rose by $733,511, for a sum of $2.9 million. In accordance with the McGill University
and Génome Québec Innovation Centre agreement, restricted net assets totalled $500,000.
Marc LePage
President and CEO Génome Québec
Denis Bilodeau
Vice President, Administration
Génome Québec
*Including communications and committees
Génome Québec
and Partners 2011-2012
Génome Québec and Activities 2011-2012
Total Investment of $50.1M
Major projects
21%
43%
Genome Canada
$30.6 M
MDEIE
36%
Other partners
Administration – net of
depreciation
$14.8 M
$0.9 M
$ 0.1 M
$ 0.7 M
Strategic initiatives
Laboratory equipment
$3 M
Investment income and others
Technology centres
11
Génome Québec
Statement of Financial Position
The Statement of Financial Position as at March 31, 2012 and 2011 and the Statement of Operations for the years ended March 31, 2012
and 2011 that follow are provided as illustrative summaries only and are not intended to replace the full financial statements of Génome
Québec. These full financial statements were audited and reported on June 12, 2012 by KPMG LLP, Chartered Professional Accountants.
Statement of Financial Position
March 31, 2012, with comparative information for 2011
2012
2011
Assets
Current assets:
Cash and cash equivalents
$10,482,241
Short-term investments
15,577,054 2,392,893
Accounts receivable and work in progress 2,492,734
Contribution receivable
—
$1,236,547
2,609,172
14,000
Advances to genomic research projects
4,584,756
Inventories
709,846
605,707
Prepaid expenses
463,095
290,349
34,309,726
7,148,668
Long-term investments
23,886,467
29,305,338
Capital assets
710,232
1,612,674
$58,906,425
$38,066,680
Accounts payable and accrued liabilities
$2,302,456
$3,337,538
Deferred revenues
418,267
—
Liabilities and Net Assets
Current liabilities:
180,606
Due to genomic research projects
–
1,884,740
Contributions to be reimbursed
–
2,448,194
Obligations related to an agreement
640,000
3,360,723
Obligations related to an agreement
919,221
—
7,851,078
—
Deferred contributions:
Future expenses
50,501,524
Capital assets
479,631 1,129,177
25,607,372
50,981,155
26,736,549
Unrestricted
2,914,725
2,181,214
Restricted - invested in capital assets
230,601
483,497
Restricted - Technology investment and contingency fund
500,000
814,342
3,645,326
3,479,053
Net assets:
$58,906,425
12
$38,066,680
Statement of Operations
Year ended March 31, 2012, with comparative information for 2011
2012
2011
Revenues:
Amortization of deferred contributions related
to expenses
$21,895,838
$29,079,116
Amortization of deferred contributions related
to capital assets
767,407
752,079
Investment income
914,255
480,013
Revenues from technology centres
12,777,166
12,199,280
Revenues from intellectual property and others
110,162
107,382
36,464,828
42,617,870
Genomic research projects
14,341,834
22,301,749
Technology centres operational costs
15,411,328
14,178,589
Projects - Technology investment and contingency fund
926,028
358,725
General and administrative
2,512,071
3,215,270
Communications and public outreach
272,960
335,686
Committees
82,061
213,022
Strategic initiatives
688,473
208,460
Depreciation of capital assets
767,407
752,079
Depreciation of restricted capital assets
377,172
258,502
35,379,334
41,822,082
$1,085,494
$795,788
Expenses:
Excess of revenues over expenses
13
Génome Québec
MEMBERS OF THE
BOARD OF DIRECTORS,
COMMITTEES
BOARD OF DIRECTORS
Chairman of the Board
Martin Godbout, PhD
Vice Chairman of the Board
Daniel Bouthillier, PhD, MBA
President and CEO, Kaneq Pharma
MANAGEMENT COMMITTEE
Marc LePage
President and CEO
Génome Québec
Denis Bilodeau
Vice President, Administration
Marie-Kym Brisson
Vice President, Public Affairs and Communications
Claude Lamarre
Director, Finance
Catalina Lopez Correa
Vice President, Scientific Affairs
Daniel Tessier
Senior Director, Operations and
Business Development
Secretary Treasurer of the Board
Mr. Jean Brunet
Attorney, Managing Partner of Stein Monast L.L.P.
BOARD MEMBERS
Hélène Desmarais, C.M., LL.D.
CEO and Chair of the Board of Administration of the
Centre d’entreprises et d’innovation de Montréal
Jean-Paul Gagné, ASC
Corporate Director
Publisher Emeritus, Journal Les Affaires
Raymond Langlois, CPA, CA
Vice President, Portfolio Manager
RBC Dominion Securities
Marc LePage
President and CEO
Génome Québec
Monique Létourneau, ICD.D, CFA, M.Sc.
President, Défistratège
GOVERNANCE COMMITTEE
Chairman of the Committee
Jean-Paul Gagné, ASC
Corporate Director
Publisher Emeritus, Journal Les Affaires
Secretary of the Committee
Mr. Jean Brunet
Attorney, Managing Partner of Stein Monast L.L.P.
Martin Godbout, PhD
AUDIT AND INVESTMENT COMMITTEES
Chairman of the Committee
Jean-Paul Gagné, ASC
Corporate Director
Publisher Emeritus, Journal Les Affaires
Rémi Quirion, O.C., Ph.D., FRSC, CQ
Chief Scientist of Québec
Daniel Bouthillier, PhD, MBA
President and CEO, Kaneq Pharma
Paule Têtu, F. Eng., M.Sc.
Vice President, Strategic Development,
Del Degan, Massé and Associates
Raymond Langlois, CPA, CA
Vice President, Portfolio Manager
RBC Dominion Securities
Monique Létourneau, ICD.D, CFA, M.Sc.
President, Défistratège
OBSERVERS
Luc Castonguay
Director General
General Directorate of Research, Innovation,
Science and Society, Ministry of Economic
Development, Innovation and Export Trade
Pierre Meulien, PhD
President and CEO
Genome Canada
HUMAN RESOURCES COMMITTEE
Chairman of the Committee
Martin Godbout, PhD
Secretary of the Committee
Mr. Jean Brunet
Attorney, Managing Partner of Stein Monast L.L.P.
Daniel Bouthillier, PhD, MBA
President and CEO, Kaneq Pharma
Jean-Paul Gagné, ASC
Corporate Director
Publisher Emeritus, Journal Les Affaires
Marc LePage
President and CEO
Génome Québec
Chairman of the Committee
Martin Godbout, PhD
Secretary of the Committee
Mr. Jean Brunet
Attorney, Managing Partner of Stein Monast L.L.P.
Rémi Quirion, O.C., Ph.D., FRSC, CQ
Chief Scientist of Québec
Paule Têtu, F. Eng., M.Sc.
Vice President, Strategic Development,
Del Degan, Massé and Associates
EXECUTIVE COMMITTEE
14
Daniel Bouthillier, PhD, MBA
President and CEO, Kaneq Pharma
STRATEGIC AND SCIENTIFIC
ADVISORY BOARD (SSAB)
Chairman of the SSAB
Camille Limoges, PhD
Jo Bury, PhD, MBA
VIB
Mark McCarthy, PhD
Wellcome Trust, Oxford
Teri Manolio, MD, PhD
National Institutes of Health (NIH)
Génome Québec
LIST OF EMPLOYEES
GÉNOME QUÉBEC EMPLOYEES
ANNE-MARIE ALARCO
STEVE ARSENAULT
VICKY ARSENAULT
FRANÇOIS-MARIE BACOT
YOLANDE BASTIEN
ALEXANDRE BELISE
LINE BENGUEREL
DENIS BILODEAU
MICHAL BLAZEJCZYK
CAROLINA BOCANEGRA
DANIEL BOISMENU
JULIE BOUDREAU
MATHIEU BOURGEY
GUILLAUME BOURQUE
GENEVIÈVE BOURRET
MARIE-KYM BRISSON
SÉBASTIEN BRUNET
DAVID BUJOLD
FRANÇOIS CANTIN
MAXIME CARON
VALÉRIE CATUDAL
CHRISTINE CELLIER
FANNY CHAGNON
MARIE-PAULE CHOQUETTE
CRISTINA CIURLI
MARTIN CONSTANTINEAU
CATHERINE CÔTÉ
GENEVIÈVE DANCAUSSE
PHILIPPE DAOUST
BURAK DEMIRTAS
JOANNA DIAS
MARCOS RAFAEL DI FALCO
HAIG DJAMBAZIAN
NATHALIE ÉMOND
JOËLLE FONTAINE
HÉLÈNE FOURNIER
NANCY FOURNIER
ROSALIE FRÉCHETTE
GENEVIÈVE GENEAU
PHILIPPE GINGRAS GÉLINAS
CLAIRE GOGUEN
DANIEL GUERTIN
ISABELLE GUILLET
NATHALIE HAMEL
NATHALY HÉBERT
CECILIA HERNANDEZ
LOUIS DUMOND JOSEPH
ÉVA KAMMER
DANIELLE KEMMER
FRANÇOIS KORBULY
AUDREY ANNE KUSTEC
SYLVIE LABOISSIÈRE
MARC-ANDRÉ LABONTÉ
CLAUDE LAMARRE
NATACHA LEBRASSEUR
FABIENNE LEFEBVRE
MARC LEPAGE
PIERRE LEPAGE
DARIE LESSARD
LOUIS LÉTOURNEAU
GINETTE LEVASSEUR
GARY LÉVEQUE
CATALINA LOPEZ CORREA
STÉPHANIE LORD-FONTAINE
AURÉLIE MASUREL
TERRANCE MCQUILKIN
MARC MICHAUD
JANA MICKOVA
ALEXANDRE MONTPETIT
THUONG NGO
DANIEL PÉPIN
ANDRÉ PONTON
JEAN-MARC PROULX
FREDERICK ROBIDOUX
SHAREN SOPHIE ROLAND
JONATHAN ROUX
LINE ROY
LORRAINE SAULE
LAURA SBARRA
JEREMY SCHWARTZENTRUBER
ÉTIENNE SDICU
ALFREDO STAFFA
DANIEL TESSIER
LOUISE THIBAULT
BELISLE TIR
THAY LENG TONY TIR
VINCENT TRUDEL
JULIE VALLÉE
TU LINH VAN
ANNIE VERVILLE
DANIEL VINCENT
HOAI-THU VO
GRÉGORY VOISIN
PATRICK WILLETT
HAO FAN YAM
CHUNG-YAN YUEN
Corine Zotti
15
Génome Québec
Large-scale projects outcomes
Number of persons
employed in the 4th
Quarter 2011-2012
Number of scientists
trained in the 4th
Quarter 2011-2012
Number of
publications
accepted or
submitted
Number of
conferences
as speaker
Number of
declaration
of inventions
or patents
Project
starting
date
14
5
1
2
0
October 2009
20,3
6
11
55
8
October 2009
Peter Facchini - UAlberta/Vincent Martin - Concordia • Phytometasyn
(Synthetic Biosystems for the Production of High Value Plant Metabolites)
38
24
11
24
1
October 2009
Richard Gold - McGill • Valgen (Value Addition Through Genomics)
20
4
6
13
0
October 2009
92,3
39
29
94
9
27
16
15
20
0
July 2011
July 2011
ABC COMPETITION
Thomas Bureau - McGill • VEGI (crop improvement)
Adrian Tsang - Concordia • Genozymes (Bioproducts and
Bioprocesses Development)
Total
2010 Large-Scale Applied Research Project Competition (LSARP)
John MacKay - ULaval /Jörg Bohlman - UBC • SMarTForest
(Sustainable Forestry)
B. Franz Lang/Mohamed Hijri - UdeM • GenoRem (Decontaminating Soil)
35
15
1
10
0
Total
62
31
16
30
0
Denis J. Garand - ULaval • BEST in Genomics!
(Optimize the Transfer of Knowledge)
2
1
1
7
0
Total
2
1
1
7
0
Gregor Andelfinger - CHU Ste-Justine • Congenital Heart Disease
3
3
0
1
0
October 2010
Guy A. Rouleau - CHUM • Bipolar Disorder
7
0
2
0
0
October 2010
Guy Sauvageau - IRIC • Acute Myeloid Leukemia
11
2,6
1
4
0
October 2010
John H. White - McGill • Tuberculosis
6
3
1
4
0
October 2010
2,3
1,3
1
3
0
October 2010
Entrepreneurship Education in Genomics (EEG) Program
October 2011
GQ HEALTH COMPETITION
Ken Dewar - McGill • Digestive problems
Mark Basik - Lady Davis Institute • Breast Cancer
5
3,5
2
2
0
October 2010
Michael Hallet - McGill • Breast Cancer
4,21
0,5
2
2
1
October 2010
Alain Moreau - CHU Ste-Justine • Diagnostic Tool for Pediatric Scoliosis
10,4
4
1
8
0
October 2010
Michel G. Bergeron - ULaval • Rapid Diagnostic Tests
12
0,5
0
7
1
October 2010
Maryam Tabrizian - McGill • Portative Biosensors
5,3
5
6
5
0
October 2010
Paul Goodyer - CUSM • Cell therapy of cystinosis
5
1
1
3
0
October 2010
8,18
3,7
5
16
0
October 2010
4
1
0
2
0
October 2010
83,39
29,1
22
57
2
Jamie Engert - CUSM • Heart Disease
3
0
0
0
0
October 2010
Julie St-Pierre - McGill • Breast Cancer
1
2
1
1
0
October 2010
Pierre Drapeau/Edor Kabashi - UdeM • New Therapeutic Approaches
3
1
0
4
0
October 2010
Pavel Hamet - CHUM • Type 2 Diabetes
Gordon Shore/Michel L. Tremblay - McGill • Cancer Therapy
Total
GQ PILOT PROJECTS COMPETITION
3,4
1
2
5
0
October 2010
Sarah Kimmins - McGill • Infertility
Roger C. Levesque - ULaval • Budwork EcoGenomics
3
2
1
3
0
October 2010
Zoha Kibar - CHU Ste-Justine • Neural Tube Defects
1
0
0
0
0
October 2010
14,4
6
4
13
0
Total
QUÉBEC VERT COMPETITION
16
François Belzile - ULaval • GreenSNPs (Environmental Genomics)
Startup
January 2012
Connie Lovejoy - ULaval • CATG (Genomics for the Arctic Environment)
Startup
January 2012
Vincent Martin - Concordia • PAYGE (Reducing Fossil Fuels Dependency)
Startup
January 2012
COMPETITION TOTAL (projects in progess)
254,09
106,1
72
201
11
Génome Québec
Assessment of completed projects
Number of
persons
employed
in person-years
Number of
scientists trained
in person-years
Number of
publications
accepted or
submitted
Number of
conferences
as speaker
Number of
declaration
of inventions
or patents
Project
duration
Michel G. Bergeron - CHUQ • Theranostic Technologies (Diagnostic Tests to identify microbes
causing infections)
118
25
25
58
11
3.25 years
Deming Xu - Privé • Chemogenomics (New Therapeutic Treatments for Life-Threatening
Fungal Infections)
32
2
8
4
1
3 years
Thomas J. Hudson - McGill • ARCTIC (Colorectal Cancerl)
42
6
19
15
9
3.25 years
Franz Lang - UdeM • Protist EST (Evolution of Eukaryotic cells and Corresponding Genes)
49
21
20
18
0
3.5 years
Competitions I & II, HEALTH
Bussey/Michnick - McGill • Model Organisms (Genetic Interaction in Eukaryotic cells)
20
4
18
55
0
4 years
John J.M. Bergeron - McGill • Protéomique (Function and Structure of Genes and Proteins)
174
67
42
125
7
4 years
Fernand Labrie - ULaval • Atlas (Profiles of Steroid Action)
347
120
49
29
2
5 years
Bartha Maria Knoppers - McGill • GE3LS (Genomics and Society)
38
20
83
153
0
4 years
Fathey Sarhan - UQAM • Abiotic Stress Québec (Improve Agricultural Productivity)
82
28
11
17
0
4 years
Thomas J. Hudson - McGill • Regulatory Genetics (Identification of Regulatory Polymorphisms
in the Human Genome)
117
27
16
51
6
4 years
Rafick-Pierre Sékaly - UdeM • S2K (Immune Response)
194
79
17
150
6
4 years
Mario Fillion - McGill • IGWH (Women’s Health)
36
5
1
10
4
3 years
Sherif Abou Elela - USherbrooke • MoNa (Genome Wide Analysis of Gene Function)
51
8
6
9
2
3 years
Adrian Tsang - Concordia • Enzymes fongiques (Environmental Remediation)
167
69
16
22
8
3 years
Benoît Coulombe - UdeM • Regulatory Networks (Decoding Genetic Information)
189
63
15
111
0
3.5 years
John MacKay - ULaval • Arborea I (Health of Trees)
98
31
23
63
2
3.5 years
Thomas J. Hudson - McGill • HapMap (Genetic Research)
34
2
14
87
1
3 years
Emil Skamene - McGill • Congenic Mice (Dissect Complex Traits Relevant to Human Health)
60
13
2
11
3
4.25 years
Guy Rouleau - UdeM • Ionic Channels (Hereditary Neurological Disorder)
40
5
0
16
3
4.25 years
Terry Roemer - Private • Candida albicans (Antifungal Drug Discovery)
51
0
2
3
3
3 years
Barry Posner/Rob Sladek - McGill • Type 2 Diabetes
5
0
25
35
6
5.5 years
Bartha Maria Knoppers - McGill • GPH (Genomics and Public Health)
5
4
22
47
0
January
2006
101,48
10,82
11
28
3
5.25 years
Ken Dewar - McGill • Vervet Monkey (Neuro-development and Neurological Degradation)
18,3
2
3
4
0
4.75 years
Tomi M. Pastinen - McGill • GRID (Gene Regulators)
213
51,5
84
42
2
4.5 years
Guy A. Rouleau - UdeM • S2D (Brain Diseases)
86,03
12
4
40
1
5 years
Jean-Claude Tardif - ICM • Pharmacogenomics (Cardiovascular Disease)
346
41
15
87
0
4 years
John MacKay - Ulaval • Arborea II (Improve Productivity of Forests Products)
186
66,6
49
95
0
5 years
Bartha Maria Knoppers/Thomas J. Hudson - McGill • P G/CaG (Populations Genomics)
33,5
24
35
54
0
3 years
Daniel Lamarre/Sylvain Meloche - IRIC • IRIC • RNA Platform (New Targeted Therapies for Cancer)
16,84
0
0
3
0
2 years
Rafick-Pierre Sékaly - UdeM • NIML Platform (Vaccines and Immune Therapeutics)
18
3
4
5
2
2 years
Michel G. Bergeron - CHUQ • GPOCT (Infectiology)
45
2
9
18
1
2.25 years
Michael Phillips/Jean-Claude Tardif - ICM • Via-PGX (Cardiovascular Pharmacogenomics)
17,5
3,6
4
44
0
2.5 years
Maryam Tabrizian - McGill • DevTab (Biomarkers Discovery and Validation)
35,3
15,21
34
13
0
2 years
6
1
2
4
0
2 years
832
688
Competition III, International Consortium Initiative, Privac, Technology Development Competition
Sherif Abou Elela - USherbrooke • FAESI (Alternative Splicing)
3
Rafick-Pierre Sékaly/Ryan Brinkman - UdeM-BCCA • DevSek (Immune System)
Total Completed projects
3 072
1 526
83
17
630 René-Lévesque Blvd West, Suite 2660
Montréal (Québec) H3B 1S6
Phone: 514 398-0668 • Fax: 514 398-0883
[email protected] • www.genomequebec.com